Literature DB >> 32729280

Point-of-care hepatitis C screening with direct access referral to improve linkage to care among halfway house residents: a pilot randomised study.

John Chen Hsiang1,2,3, Pream Sinnaswami4, Mui Yok Lee1, Meng Meng Zhang1, Kwang Ee Quek5, Keng Hwee Tan5, Yew Meng Wong5, Prem Harichander Thurairajah1,3,6.   

Abstract

INTRODUCTION: Linkage to care among individuals with substance misuse remains a barrier to the elimination of the hepatitis C virus (HCV). We aimed to determine whether point-of-care (PoC) education, screening and staging for liver disease with direct access to hospitals would improve linkage to care among this group.
METHODS: All participants were offered PoC education and HCV screening. HCV-positive participants were randomised to standard care (controls) or direct access, which provided a direct pathway to hospitals. Linkage to care was determined by reviewing electronic medical records. Linkage of care cascade was defined as attendance at the specialist clinic, confirmation of viraemia by HCV RNA testing, discussion about HCV treatment and initiation of treatment.
RESULTS: 351 halfway house residents were screened. The overall HCV prevalence was 30.5% (n = 107), with 69 residents in the control group and 38 in the direct access group. The direct access group had a significantly higher percentage of cases linked to specialist review for confirmatory RNA testing (63.2% vs. 40.6%, p = 0.025), HCV treatment discussion (p = 0.009) and treatment initiation (p = 0.01) compared to the controls. Overall, only 12.6% (n = 13) had treatment initiation during follow-up. PoC HCV screening with direct access referral had significantly higher linkage to HCV treatment initiation (adjusted odds ratio 9.13, p = 0.005) in multivariate analysis.
CONCLUSION: PoC HCV screening with direct access improves linkage to care and simplifies the HCV care cascade, leading to improved treatment uptake. PoC education, screening, diagnosis and treatment may be an effective strategy to achieving HCV micro-elimination in this population. Copyright: © Singapore Medical Association.

Entities:  

Keywords:  hepatitis C care cascade; linkage to care; people who inject drugs; point of care

Mesh:

Substances:

Year:  2020        PMID: 32729280      PMCID: PMC9251228          DOI: 10.11622/smedj.2020116

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   3.331


  19 in total

Review 1.  Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.

Authors: 
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-12-16

2.  Prevalence of antibodies to hepatitis C virus in relation to surrogate markers in a blood donor population of Singapore.

Authors:  P Kuperan; A T Choon; S H Ding; G Lee
Journal:  Southeast Asian J Trop Med Public Health       Date:  1993       Impact factor: 0.267

3.  Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study.

Authors:  Jisoo A Kwon; Gregory J Dore; Jason Grebely; Behzad Hajarizadeh; Rebecca Guy; Evan B Cunningham; Cherie Power; Chris Estes; Homie Razavi; Richard T Gray
Journal:  J Viral Hepat       Date:  2018-11-14       Impact factor: 3.728

4.  Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia.

Authors:  B Hajarizadeh; J Grebely; G V Matthews; M Martinello; G J Dore
Journal:  J Viral Hepat       Date:  2018-02-19       Impact factor: 3.728

5.  The impact of a managed care network on attendance, follow-up and treatment at a hepatitis C specialist centre.

Authors:  J M Tait; P G McIntyre; S McLeod; D Nathwani; J F Dillon
Journal:  J Viral Hepat       Date:  2010-10       Impact factor: 3.728

6.  Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study.

Authors:  A D Marshall; M Micallef; A Erratt; J Telenta; C Treloar; H Everingham; S C Jones; N Bath; D How-Chow; J Byrne; P Harvey; A Dunlop; M Jauncey; P Read; T Collie; G J Dore; J Grebely
Journal:  Int J Drug Policy       Date:  2015-07-16

7.  Seroprevalence of hepatitis C in intravenous opioid users presenting in the early phase of injecting drug use in Singapore.

Authors:  M Winslow; M Subramaniam; W L Ng; A Lee; G Song; Y H Chan
Journal:  Singapore Med J       Date:  2007-06       Impact factor: 1.858

8.  A study on the epidemiology of hepatitis C infection among blood donors in Singapore.

Authors:  J E Wang
Journal:  J Public Health Med       Date:  1995-12

9.  The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries.

Authors:  Andrew M Hill; Sanjay Nath; Bryony Simmons
Journal:  J Virus Erad       Date:  2017-07-01

10.  Chronic hepatitis C virus (HCV) disease burden and cost in the United States.

Authors:  Homie Razavi; Antoine C Elkhoury; Elamin Elbasha; Chris Estes; Ken Pasini; Thierry Poynard; Ritesh Kumar
Journal:  Hepatology       Date:  2013-05-06       Impact factor: 17.425

View more
  3 in total

1.  What is required for achieving hepatitis C virus elimination in Singapore? A modeling study.

Authors:  Antoine Chaillon; Prem Harichander Thurairajah; John Chen Hsiang; Natasha K Martin
Journal:  J Gastroenterol Hepatol       Date:  2020-09-03       Impact factor: 4.029

2.  Peer support in small towns: A decentralized mobile Hepatitis C virus clinic for people who inject drugs.

Authors:  Håvard Midgard; Ronny Bjørnestad; Maren Egeland; Eivin Dahl; Ane-Kristine Finbråten; Knut B Kielland; Martin Blindheim; Olav Dalgard
Journal:  Liver Int       Date:  2022-04-12       Impact factor: 8.754

3.  Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.

Authors:  Jisoo A Kwon; Gregory J Dore; Behzad Hajarizadeh; Maryam Alavi; Heather Valerio; Jason Grebely; Rebecca Guy; Richard T Gray
Journal:  PLoS One       Date:  2021-09-16       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.